Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Mai 2025 05:28 ET | Quelle: Research and Markets

CDK9 Inhibitor Pipeline Insight Report 2025: In-Depth Insights Into 15+ Companies and 15+ Drugs in the CDK9 Inhibitor Pipeline, Including Dinaciclib, KB-0742, and Alvocidib

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "CDK9 Inhibitor - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. The "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor...
15. April 2024 11:28 ET | Quelle: Research and Markets

Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Pipeline Research Report 2024: Drugs in Development, Therapeutics Scenario and Growth Prospects

Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Cyclin-Dependent Kinase 9 (CDK9) Inhibitor - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's...
12. April 2024 07:29 ET | Quelle: Research and Markets

CDK9 inhibitor Drug Pipeline Research Report 2024

Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "CDK9 inhibitor - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering."Cyclin-Dependent Kinase 9 (CDK9)...
01. April 2024 09:15 ET | Quelle: Cyclacel

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J.,...